 Joseph Sottnik
Concepts (161)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 8 | 2015 | 250 | 2.560 |
Why?
| | Osteosarcoma | 7 | 2014 | 75 | 2.350 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2021 | 250 | 1.280 |
Why?
| | Dog Diseases | 3 | 2010 | 62 | 0.970 |
Why?
| | Hyaluronan Receptors | 2 | 2021 | 103 | 0.820 |
Why?
| | Prostatic Neoplasms | 4 | 2015 | 1033 | 0.800 |
Why?
| | Genital Neoplasms, Female | 1 | 2024 | 88 | 0.780 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2021 | 1400 | 0.750 |
Why?
| | Carcinoma, Lobular | 1 | 2021 | 49 | 0.690 |
Why?
| | Breast Neoplasms | 2 | 2024 | 2243 | 0.660 |
Why?
| | Receptors, Androgen | 1 | 2021 | 149 | 0.650 |
Why?
| | Glycogen Debranching Enzyme System | 1 | 2019 | 3 | 0.630 |
Why?
| | Receptors, Estrogen | 1 | 2021 | 435 | 0.580 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2021 | 429 | 0.570 |
Why?
| | Cell Proliferation | 6 | 2021 | 2471 | 0.550 |
Why?
| | Cell Cycle Proteins | 1 | 2021 | 614 | 0.540 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 1271 | 0.480 |
Why?
| | Pressure | 1 | 2015 | 243 | 0.430 |
Why?
| | Neoplasm Metastasis | 4 | 2018 | 658 | 0.430 |
Why?
| | Dogs | 5 | 2014 | 411 | 0.420 |
Why?
| | Integrin alpha2beta1 | 1 | 2012 | 3 | 0.410 |
Why?
| | Extracellular Matrix Proteins | 1 | 2014 | 153 | 0.410 |
Why?
| | Osteoclasts | 1 | 2013 | 52 | 0.410 |
Why?
| | Cell Line, Tumor | 8 | 2021 | 3396 | 0.380 |
Why?
| | Wnt4 Protein | 2 | 2024 | 18 | 0.380 |
Why?
| | Phosphoproteins | 1 | 2014 | 338 | 0.380 |
Why?
| | Antimetabolites | 1 | 2011 | 23 | 0.370 |
Why?
| | Neovascularization, Pathologic | 2 | 2010 | 300 | 0.370 |
Why?
| | Deoxyglucose | 1 | 2011 | 52 | 0.360 |
Why?
| | Tumor Microenvironment | 1 | 2015 | 682 | 0.350 |
Why?
| | Interleukin-11 Receptor alpha Subunit | 1 | 2010 | 4 | 0.340 |
Why?
| | Lymphocyte Count | 1 | 2010 | 150 | 0.340 |
Why?
| | Oxidative Phosphorylation | 1 | 2011 | 193 | 0.340 |
Why?
| | Mice | 12 | 2021 | 17775 | 0.340 |
Why?
| | Biopsy, Fine-Needle | 1 | 2010 | 68 | 0.340 |
Why?
| | Luciferases | 1 | 2010 | 151 | 0.320 |
Why?
| | Glycolysis | 1 | 2011 | 319 | 0.320 |
Why?
| | Tumor Burden | 1 | 2010 | 309 | 0.310 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2010 | 346 | 0.280 |
Why?
| | Osteomyelitis | 1 | 2009 | 131 | 0.280 |
Why?
| | Pyrazoles | 1 | 2010 | 422 | 0.270 |
Why?
| | Flow Cytometry | 1 | 2010 | 1185 | 0.260 |
Why?
| | Animals | 13 | 2021 | 36915 | 0.260 |
Why?
| | Mice, Nude | 3 | 2021 | 696 | 0.260 |
Why?
| | Mice, Inbred C3H | 3 | 2011 | 272 | 0.250 |
Why?
| | Blotting, Western | 4 | 2013 | 1227 | 0.240 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 950 | 0.230 |
Why?
| | Wnt Signaling Pathway | 2 | 2019 | 193 | 0.230 |
Why?
| | Osteocytes | 2 | 2015 | 28 | 0.230 |
Why?
| | Staphylococcal Infections | 1 | 2009 | 398 | 0.230 |
Why?
| | Carbonyl Reductase (NADPH) | 1 | 2024 | 5 | 0.220 |
Why?
| | Parathyroid Hormone-Related Protein | 2 | 2013 | 24 | 0.210 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1255 | 0.200 |
Why?
| | Disease Models, Animal | 2 | 2010 | 4281 | 0.200 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2024 | 193 | 0.190 |
Why?
| | Ligands | 1 | 2024 | 665 | 0.180 |
Why?
| | Osteoblasts | 2 | 2014 | 126 | 0.180 |
Why?
| | MCF-7 Cells | 1 | 2021 | 127 | 0.180 |
Why?
| | Angiogenesis Inhibitors | 2 | 2013 | 226 | 0.170 |
Why?
| | Breast | 1 | 2021 | 153 | 0.170 |
Why?
| | Tamoxifen | 1 | 2021 | 199 | 0.170 |
Why?
| | Fluorescent Antibody Technique | 2 | 2011 | 386 | 0.160 |
Why?
| | Wnt3A Protein | 1 | 2019 | 10 | 0.160 |
Why?
| | Neoplasm Transplantation | 2 | 2010 | 256 | 0.160 |
Why?
| | Acyltransferases | 1 | 2019 | 56 | 0.160 |
Why?
| | Butylhydroxybutylnitrosamine | 1 | 2019 | 6 | 0.160 |
Why?
| | In Vitro Techniques | 2 | 2011 | 1108 | 0.150 |
Why?
| | Signal Transduction | 2 | 2024 | 5077 | 0.150 |
Why?
| | Chloroquine | 1 | 2018 | 52 | 0.150 |
Why?
| | Genetic Engineering | 1 | 2019 | 92 | 0.150 |
Why?
| | Neoplasms | 2 | 2010 | 2655 | 0.150 |
Why?
| | Macrolides | 1 | 2018 | 63 | 0.140 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 857 | 0.140 |
Why?
| | Lysosomes | 1 | 2018 | 142 | 0.140 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1739 | 0.140 |
Why?
| | Monocytes | 2 | 2010 | 567 | 0.130 |
Why?
| | rho Guanine Nucleotide Dissociation Inhibitor beta | 1 | 2016 | 4 | 0.130 |
Why?
| | Osteopontin | 1 | 2016 | 34 | 0.130 |
Why?
| | Humans | 13 | 2024 | 136899 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 451 | 0.130 |
Why?
| | Chemokine CCL5 | 1 | 2015 | 43 | 0.120 |
Why?
| | Transcriptome | 1 | 2021 | 973 | 0.110 |
Why?
| | Matrix Metalloproteinases | 1 | 2015 | 94 | 0.110 |
Why?
| | Female | 7 | 2024 | 72703 | 0.110 |
Why?
| | Lung Neoplasms | 2 | 2018 | 2490 | 0.110 |
Why?
| | Male | 8 | 2021 | 67308 | 0.110 |
Why?
| | Gene Expression Profiling | 1 | 2021 | 1769 | 0.110 |
Why?
| | Urologic Neoplasms | 1 | 2013 | 31 | 0.110 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 86 | 0.100 |
Why?
| | Osteoprotegerin | 1 | 2013 | 24 | 0.100 |
Why?
| | RANK Ligand | 1 | 2013 | 29 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 799 | 0.100 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2013 | 71 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2019 | 1167 | 0.100 |
Why?
| | Disease-Free Survival | 2 | 2013 | 690 | 0.100 |
Why?
| | Bone Resorption | 1 | 2013 | 86 | 0.100 |
Why?
| | Pyrroles | 1 | 2013 | 211 | 0.100 |
Why?
| | Prognosis | 1 | 2021 | 4011 | 0.100 |
Why?
| | Apoptosis | 1 | 2021 | 2542 | 0.090 |
Why?
| | Mice, Knockout | 1 | 2019 | 2998 | 0.090 |
Why?
| | Cathepsin L | 1 | 2011 | 9 | 0.090 |
Why?
| | DNA Primers | 1 | 2012 | 514 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2013 | 379 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2013 | 2140 | 0.090 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2010 | 79 | 0.090 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 974 | 0.090 |
Why?
| | Indoles | 1 | 2013 | 411 | 0.080 |
Why?
| | Transplantation, Heterologous | 1 | 2010 | 195 | 0.080 |
Why?
| | Stem Cells | 1 | 2014 | 589 | 0.080 |
Why?
| | Cell Adhesion | 1 | 2011 | 466 | 0.080 |
Why?
| | Carboplatin | 1 | 2010 | 144 | 0.080 |
Why?
| | Microvessels | 1 | 2010 | 86 | 0.080 |
Why?
| | Base Sequence | 1 | 2012 | 2180 | 0.080 |
Why?
| | Mice, Inbred Strains | 1 | 2009 | 413 | 0.080 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2010 | 285 | 0.080 |
Why?
| | Interleukin-6 | 1 | 2013 | 771 | 0.080 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 277 | 0.070 |
Why?
| | Tibia | 1 | 2010 | 177 | 0.070 |
Why?
| | Oxygen Consumption | 1 | 2011 | 681 | 0.070 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 5766 | 0.070 |
Why?
| | Doxorubicin | 1 | 2010 | 363 | 0.070 |
Why?
| | Transfection | 1 | 2010 | 948 | 0.070 |
Why?
| | Bone and Bones | 1 | 2010 | 317 | 0.070 |
Why?
| | Cell Movement | 1 | 2011 | 971 | 0.070 |
Why?
| | Survival Analysis | 1 | 2010 | 1320 | 0.070 |
Why?
| | Survival Rate | 1 | 2011 | 1972 | 0.070 |
Why?
| | Cell Differentiation | 1 | 2014 | 1976 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2009 | 444 | 0.060 |
Why?
| | Endothelial Cells | 1 | 2010 | 779 | 0.060 |
Why?
| | Cell Line | 1 | 2010 | 2847 | 0.060 |
Why?
| | RNA, Small Interfering | 2 | 2019 | 620 | 0.060 |
Why?
| | Immunity, Innate | 1 | 2009 | 832 | 0.050 |
Why?
| | Chronic Disease | 1 | 2009 | 1773 | 0.050 |
Why?
| | Phenotype | 1 | 2011 | 3201 | 0.050 |
Why?
| | Macrophages | 1 | 2009 | 1547 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2019 | 111 | 0.040 |
Why?
| | Time Factors | 1 | 2010 | 6802 | 0.040 |
Why?
| | Paracrine Communication | 1 | 2019 | 64 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2019 | 240 | 0.040 |
Why?
| | Inhibitor of Differentiation Proteins | 1 | 2018 | 2 | 0.040 |
Why?
| | Protein Transport | 1 | 2019 | 443 | 0.040 |
Why?
| | RNA Interference | 1 | 2019 | 463 | 0.040 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2019 | 221 | 0.030 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2019 | 455 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 432 | 0.030 |
Why?
| | Early Termination of Clinical Trials | 1 | 2013 | 16 | 0.030 |
Why?
| | Sample Size | 1 | 2013 | 118 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2013 | 55 | 0.030 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2013 | 139 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 344 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 329 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 784 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2013 | 892 | 0.020 |
Why?
| | beta Catenin | 1 | 2013 | 251 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2013 | 543 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 1980 | 0.020 |
Why?
| | Disease Progression | 1 | 2013 | 2744 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2013 | 10768 | 0.010 |
Why?
| | Aged | 1 | 2013 | 23641 | 0.010 |
Why?
| | Middle Aged | 1 | 2013 | 33118 | 0.010 |
Why?
| | Adult | 1 | 2013 | 37595 | 0.010 |
Why?
|
|
Sottnik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|